Cell Signaling Technology, Inc.

Charles Farnsworth

Ailan Guo

Klarisa Rikova

Albrecht Moritz

Yu Li

Ting-Lei Gu

Jian Yu

Anthony Paul Possemato

Kimberly A Lee

John Rush

Peter Hornbeck

Valerie Goss

Jeffrey Joseph Mitchell

Robert Polakiewicz

Matthew Stokes

Erik Spek

Jessica Cherry

Corinne Michaud

The invention discloses 482 novel phosphorylation sites identified in carcinoma and/or leukemia, peptides (including AQUA peptides) comprising a phosphorylation site of the invention, antibodies specifically bind to a novel phosphorylation site of the invention, and diagnostic and therapeutic uses of the above.

Tyrosine phosphorylation sites

The invention discloses 168 novel phosphorylation sites identified in signal transduction proteins and pathways downstream of, and including, EGFR kinase, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: Actin Binding proteins, Adaptor/Scaffold proteins, Calcium-Binding Proteins, Cell Cycle Regulation proteins, Cytoskeletal proteins, DNA Binding and Replication Proteins, GTPase Activating proteins, Guanine Nucleotide Exchange Factor proteins, Lipid Kinases, Receptor Tyrosine Kinases, Receptor Tyrosine Kinase ligands, Protein Kinases, Receptor and Protein Phosphatases, Transcription Factor proteins, Tumor Suppressor proteins, and Vesicle proteins.

Reagents for the detection of protein phosphorylation in EGFR-signaling pathways

Growing community of inventors

Concord, MA, United States of America

Charles Farnsworth